1. Home
  2. MDIA vs CGTX Comparison

MDIA vs CGTX Comparison

Compare MDIA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mediaco Holding Inc.

MDIA

Mediaco Holding Inc.

SELL

Current Price

$0.96

Market Cap

90.7M

ML Signal

SELL

CGTX

Cognition Therapeutics Inc.

SELL

Current Price

$0.58

Market Cap

79.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MDIA
CGTX
Founded
2019
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.7M
79.6M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
MDIA
CGTX
Price
$0.96
$0.58
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $3.33
AVG Volume (30 Days)
9.1K
★ 376.9K
Earning Date
11-16-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 62.79
EPS
N/A
★ N/A
Revenue
★ $133,336,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 39.52
N/A
52 Week Low
$0.54
$0.55
52 Week High
$1.64
$1.81

Technical Indicators

Market Signals
Indicator
MDIA
CGTX
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
MDIA
CGTX

About MDIA Mediaco Holding Inc.

MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: